Advice
Following a full submission
Buprenorphine (Transtec) patch is not recommended for use within NHS Scotland for the treatment of moderate to severe cancer pain and severe pain that does not respond to nonopioid analgesics.
No comparative data have been provided with alternative transdermal or oral opioid preparations. The case for buprenorphine patches as a cost-minimising option when compared to the other transdermal opioid preparation marketed in the UK was not demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- Buprenorphine (Transtec®) matrix patches
- SMC ID:
- 116/04
- Indication:
- Moderate to severe cancer pain and severe pain that does not respond to non-opioid analgesics
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 September 2004